Janus Henderson Investors US’s Myriad Genetics MYGN Stock Holding History

Janus Henderson Investors US’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-18,300	Closed	-$622K	–	1198
2015 Q2	$622K	Sell	18,300 -7,400	-29%	-$252K	﹤0.01%	1013
2015 Q1	$910K	Sell	25,700 -22,800	-47%	-$816K	﹤0.01%	962
2014 Q4	$1.65M	Buy	48,500 +6,300	+15%	+$224K	﹤0.01%	930
2014 Q3	$1.63M	Buy	42,200 +34,500	+448%	+$1.29M	﹤0.01%	921
2014 Q2	$300K	Buy	+7,700	New	+$286K	﹤0.01%	1060
2014 Q1	–	Sell	-13,400	Closed	-$281K	–	1076
2013 Q4	$281K	Sell	13,400 -5,600	-29%	-$142K	﹤0.01%	1049
2013 Q3	$447K	Hold	19,000	–	–	﹤0.01%	992
2013 Q2	$511K	Buy	+19,000	New	+$551K	﹤0.01%	927

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Investors US's MYGN Position: Q3 2015 in Review

Janus Henderson Investors US sold out of Myriad Genetics (MYGN) in Q3 2015, closing a stake of 18,300 shares — an estimated $622K sold.

Janus Henderson Investors US first reported a position in MYGN in Q2 2013 and held it in 8 quarters. The position peaked at $1.65M in Q4 2014. 234 funds tracked by Wall St. Rank hold MYGN as of Q3 2015.

Janus Henderson Investors US reported no remaining Myriad Genetics position as of Q3 2015 after selling out during the quarter.
Janus Henderson Investors US sold 18,300 Myriad Genetics shares in Q3 2015, an estimated $622K.
Janus Henderson Investors US first reported a position in Myriad Genetics in Q2 2013 and held it in 8 quarters.
Janus Henderson Investors US's Myriad Genetics position peaked at $1.65M in Q4 2014.
234 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2015.

Based on Janus Henderson Investors US's 13F filing for Q3 2015, filed 17 Nov 2015.